Modern possibilities of molecular diagnostics contribute to improving the effectiveness of therapy against Helicobacter pylori

The effectiveness of anti-Helicobacter pylori (H.pylori) therapy depends on both host and bacterial factors.The key bacterial challenges involve antibiotic resistance, strain virulence, bacterial load, and biofilm development.Host factors include treatment adherence, level of gastric acid secretion, and polymorphisms in genes involved in the metabolism of drugs used for H. pylori eradication.Adverse allergic events occur with 1%-5% of antibiotic therapies, with genetic predispositions accounting for 60%-70% of this variability in drug hypersensitivity.This review provides a comprehensive analysis of genetic markers involved in metabolizing H. pylori eradication therapies and the associated adverse reaction risks.Furthermore, it details genotype-guided therapeutic recommendations, prognostic indicators for infection-related complications, and variables dictating treatment success.